Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

Yoichi Nakanishi, Koichi Takayama, Hiroshi Wataya, Miiru Izumi, Takahiro Minami, Koichi Takano, Koji Inoue, Shin'ichi Osaki, Kanehito Kimotsuki, Taishi Harada, Nobuyuki Hara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.

Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalCHEMOTHERAPY
Volume48
Issue number4
DOIs
Publication statusPublished - Sep 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.'. Together they form a unique fingerprint.

  • Cite this

    Nakanishi, Y., Takayama, K., Wataya, H., Izumi, M., Minami, T., Takano, K., Inoue, K., Osaki, S., Kimotsuki, K., Harada, T., & Hara, N. (2002). Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. CHEMOTHERAPY, 48(4), 205-210. https://doi.org/10.1159/000063866